Induction of abortion in mice with a monoclonal antibody specific for suppressor T-lymphocyte molecules.

J Reprod Fertil

Department of Microbiology, University of Health Sciences, Chicago Medical School, Illinois 60064.

Published: March 1988

A monoclonal antibody, mAb 14-30, which binds T-cell produced suppressor factors (TsF) was used to study the possibility that molecules produced by suppressor T-cells play a role in maintaining pregnancy, presumably by protecting the fetus from the maternal immune system. Female mice were injected with mAb 14-30 at various times after mating. Overall, only 14% of the expected 68% of the mated and treated females were pregnant at term. In addition, Western blots were used to demonstrate the presence of TsF in fetuses, placentae, uteri and spleen of pregnant animals and its presence only in the spleen of non-pregnant animals. These experiments help to confirm results that indicate the importance of immune suppressor factors in maintaining pregnancy and extend these previous observations to include suppressor T-cell molecules.

Download full-text PDF

Source
http://dx.doi.org/10.1530/jrf.0.0820691DOI Listing

Publication Analysis

Top Keywords

monoclonal antibody
8
mab 14-30
8
produced suppressor
8
suppressor factors
8
maintaining pregnancy
8
suppressor
5
induction abortion
4
abortion mice
4
mice monoclonal
4
antibody specific
4

Similar Publications

Hairy cell leukemia (HCL) is a rare, chronic B-cell malignancy with an indolent course that typically responds well to purine nucleoside analogs, such as cladribine. We present the case of a 74-year-old woman with nearly three decades of recurrent HCL, marked by multiple relapses and significant toxicities to various treatments, including purine analogs, BRAF inhibitors, BTK inhibitors, a cytoreductive agent, and the monoclonal antibody rituximab. Despite severe allergic reactions and intolerances to standard therapies, the patient achieved multiple remissions.

View Article and Find Full Text PDF

Decoding the Molecular Basis of the Specificity of an Anti-sTn Antibody.

JACS Au

January 2025

UCIBIO-Applied Molecular Biosciences Unit, Department of Chemistry, NOVA School of Science and Technology, NOVA University Lisbon, 2829-516 Caparica, Portugal.

The mucin -glycan sialyl Tn antigen (sTn, Neu5Acα2-6GalNAcα1--Ser/Thr) is an antigen associated with different types of cancers, often linked with a higher risk of metastasis and poor prognosis. Despite efforts to develop anti-sTn antibodies with high specificity for diagnostics and immunotherapy, challenges in eliciting high-affinity antibodies for glycan structures have limited their effectiveness, leading to low titers and short protection durations. Experimental structural insights into anti-sTn antibody specificity are lacking, hindering their optimization for cancer cell recognition.

View Article and Find Full Text PDF

Introduction: Rabies monoclonal antibody (mAb) is a life-saving immune-biological for postexposure prophylaxis (PEP) in all Category III animal exposures. A novel cocktail of mAbs derived using recombinant DNA technology is presently available for usage. The WHO recommends monitoring the clinical use and outcomes of mAb products.

View Article and Find Full Text PDF

Pembrolizumab is a monoclonal antibody directed against the programmed cell death-1 (PD1) receptor, which binds to PD1 receptors on T lymphocytes and blocks their inactivation by tumor cells. Pembrolizumab is not free from side effects, a rare one of which is hypocorticism. Here we present a patient with pembrolizumab-induced hypocorticism manifested by a cerebrovascular event.

View Article and Find Full Text PDF

Introduction: Although there are a number of neoadjuvant immunotherapy combinations that can be applied to the treatment of perioperative non-small cell lung cancer patients, the optimal treatment combination strategy has not yet been determined.

Methods: We searched PubMed, EMBASE, Cochrane Library, ClinicalTrials.go and randomised controlled trials (RCTs) from major international conferences for literature related to neoadjuvant immunotherapy combinations published as first-line treatment options for non-small cell lung cancer from the start of the library to 20 February 2024, and performed a systematic review and network meta-analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!